Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Filament Health Corp N.FH

Alternate Symbol(s):  FLHLF

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral... see more

Recent & Breaking News (NEO:FH)

FILAMENT HEALTH REFILES Q2 AND Q3 INTERIM FINANCIAL STATEMENTS AND MD&A

PR Newswire February 22, 2022

Filament Health (NEO:FH) receives Health Canada approval for phase 2 PEX010 clinical trial

John Ballem  January 31, 2022

FILAMENT HEALTH AND CYBIN THERAPEUTICS ANNOUNCE APPROVAL FOR PHASE II CLINICAL TRIAL FOR DEPRESSION

PR Newswire January 31, 2022

Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers

PR Newswire January 26, 2022

FILAMENT HEALTH AND CYBIN THERAPEUTICS ANNOUNCE LICENSING AGREEMENT

PR Newswire January 14, 2022

IIROC Trade Resumption - FH

PR Newswire January 5, 2022

FILAMENT HEALTH RECOGNIZES THE RESTORATION OF ACCESS TO RESTRICTED DRUGS VIA THE HEALTH CANADA SPECIAL ACCESS PROGRAM

PR Newswire January 5, 2022

IIROC Trading Halt - FH

PR Newswire January 5, 2022

FILAMENT HEALTH ANNOUNCES HEALTH CANADA APPROVAL FOR PHASE II TRIAL ADMINISTERING NEW PSILOCYBIN MICRODOSE FORMULATION

PR Newswire January 4, 2022

Filament Health to Participate in Key Psychedelics Conferences in December 2021

PR Newswire December 1, 2021

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

PR Newswire November 15, 2021

Top 5 Stories of the Week: Datametrex (TSXV:DM), Alianza Minerals (TSXV:ANZ), Group Ten Metals (TSXV:PGE), LUXXFOLIO Holdings (CSE:LUXX), Filament Health (NEO:FH)

Trevor Abes  November 5, 2021

The Power Play by The Market Herald Releases New Interviews with Filament Health, Kidoz Inc., Falcon Gold, Psyched Wellness, Maven Brands Inc., and Xali Gold Corp.

Accesswire November 3, 2021

Filament Health (NEO:FH) receives FDA authorization for psychedelic clinical trial

John Ballem  November 3, 2021

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct Psilocin Administration and First-Ever Psychedelic Botanical Drug Candidates

PR Newswire November 2, 2021

Filament Health to Webcast Live at VirtualInvestorConferences.com October 14th

PR Newswire October 13, 2021

Filament Health Announces DTC Eligibility and Up-List to the OTCQB Exchange

PR Newswire October 12, 2021

Filament Health Shares to Commence Trading on the OTC Market

PR Newswire September 7, 2021

Filament Health Files 20th Patent Application Including Three International PCT Applications

PR Newswire September 1, 2021

Filament Health Successfully Completes Industry-First Export of Natural GMP Psychedelics to the United States

PR Newswire August 26, 2021